Endoscopic Treatment of Dieulafoy Lesions and Risk Factors for Rebleeding.
10.3904/kjim.2009.24.4.318
- Author:
Won LIM
1
;
Tae Oh KIM
;
Su Bum PARK
;
Ha Rin RHEE
;
Jin Hyun PARK
;
Jung Ho BAE
;
Hong Ryeul JUNG
;
Mi Ra KIM
;
NaRiA LEE
;
Sun Mi LEE
;
Gwang Ha KIM
;
Jeong HEO
;
Geun Am SONG
Author Information
1. Department of Internal Medicine, Pusan National University College of Medicine, Busan, Korea. kto0440@yahoo.co.kr
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Dieulafoy;
Gastrointestinal hemorrhage;
Endoscopy;
Hemostasis;
Anticoagulants
- MeSH:
Adult;
Aged;
Arteriovenous Malformations/complications/*therapy;
Female;
Gastrointestinal Hemorrhage/etiology/*therapy;
Hemostasis, Endoscopic/*methods;
Humans;
Male;
Middle Aged;
Recurrence;
Risk Factors
- From:The Korean Journal of Internal Medicine
2009;24(4):318-322
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND/AIMS: Dieulafoy lesions are an important cause of upper gastrointestinal bleeding. The purpose of this study was to assess the efficacy of endoscopic treatment for these lesions and to identify the possible predictive factors for rebleeding associated with clinical and endoscopic characteristics. METHODS: Records from 44 patients admitted with Dieulafoy bleeding between January 2006 and December 2007 were reviewed. We retrospectively analyzed the clinical and endoscopic findings and then correlated the rebleeding risk factors with Dieulafoy lesions. RESULTS: Primary hemostasis was achieved by endoscopic treatment in 39 patients (88.6%). There were no significant differences between the rebleeding and non-rebleeding groups with respect to age, gender, initial hemoglobin levels, presence of shock, concurrent disease, location of bleeding, or initial hemostatic treatment methods. However, the use of non-steroidal anti-inflammatory drugs or anticoagulants (p=0.02) and active stages in the Forrest classification (p<0.01) were risk factors for rebleeding after endoscopic therapy. CONCLUSIONS: Endoscopic therapy is effective and safe for treating Dieulafoy lesions, and it has both short- and long-term benefits. Early identification of risk factors such as the use of non-steroidal anti-inflammatory drugs or anticoagulants and the Forrest classification of bleeding predict the outcome of Dieulafoy lesions.
